The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Open accessAbstract
BACKGROUND: Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint. METHODS: In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previously untreated neovascular age-related macular degeneration and a best corrected distance visual acuity (BCVA) of at least 25 letters from 23 hospitals in the UK. Participants were randomly assigned (1:1:1:1) to intravitreal injections of ranibizumab (0·5 mg) or bevacizumab (1·25 mg) in continuous (every month) or discontinuous (as needed) regimens, with monthly review. Study participants and clinical assessors were masked to drug allocation. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point investigators and participants were unmasked. The primary outcome was BCVA at 2 years, with a prespecified non-inferiority limit of 3·5 letters. The primary safety outcome was arterial thrombotic event or hospital admission for heart failure. Analyses were by modified intention to treat. This trial is registered, number ISRCTN92166560. FINDINGS: Between March 27, 2008, and Oct 15, 2010, 628 patients underwent randomisation. 18 were withdrawn; 610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses. 525 participants reached the visit at 2 years: 134 ranibizumab in continuous regimen, 137 ranibizumab in discontinuous regimen, 127 bevacizumab in continuous regimen, and 127 bevacizumab in discontinuous regimen. For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference -1·37 letters, 95% CI -3·75 to 1·01; p=0·26). Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1·63 letters, -4·01 to 0·75; p=0·18). Frequency of arterial thrombotic events or hospital admission for heart failure did not differ between groups given ranibizumab (20 [6%] of 314 participants) and bevacizumab (12 [4%] of 296; odds ratio [OR] 1·69, 95% CI 0·80-3·57; p=0·16), or those given continuous (12 [4%] of 308) and discontinuous treatment (20 [7%] of 302; 0·56, 0·27-1·19; p=0·13). Mortality was lower with continuous than discontinuous treatment (OR 0·47, 95% CI 0·22-1·03; p=0·05), but did not differ by drug group (0·96, 0·46-2·02; p=0·91). INTERPRETATION: Ranibizumab and bevacizumab have similar efficacy. Reduction in the frequency of retreatment resulted in a small loss of efficacy irrespective of drug. Safety was worse when treatment was administered discontinuously. These findings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought. FUNDING: UK National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in the IVAN study, the incidence was similar in eyes treated with ranibizumab (28%) and with bevacizumab (31%; p=0.46)”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“In CATT and all randomized clinical trials of anti-VEGF treatment for neovascular AMD, most of the improvement in mean visual acuity from baseline occurred within the first 3 to 6 months with little erosion of the benefit through 2 years when a fixed schedule of monthly (ranibizumab, bevacizumab, aflibercept) or bi-monthly (aflibercept) treatment was maintained.1,7,9,17,34”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“decreasing the likelihood of a true effect of ranibizumab on development of geographic atrophy.”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“In the IVAN study, 34% of eyes that received continuous (monthly) treatment developed geographic atrophy as compared with 26% in the discontinuous (PRN) group (p=0.03).9”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Cited by
Sorted by citations
Items 501–600 of 743
Agarwal, R., Gupta, S. K., & Agrawal, S. (2023) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1748_22 · Cited by 6
“[3] Even though bevacizumab has not been approved for use in ophthalmological practice, multiple trials have been conducted and proved it to be non‐inferior to ranibizumab in terms of safety and efficacy, including the IVAN[4] study, CATT[5] trial, MANTA[6] trial, LUCAS[7] trial, and GEFAL[8] trial.”
BackgroundMa, H., Wei, H., Zou, C., Zhu, G., Gao, Q., Zhang, N., & Wang, B. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01068-8 · Cited by 6
“In the CATT study, evaluation of fundus photographs and fluorescein angiography showed a higher likelihood of developing geographic GA with the monthly regimen compared with the PRN regimen, which was also confirmed by the IVAN trial [50, 51].”
MethodMa, C., Bai, L., Lei, C.-L., Wu, C., Shi, Q., HU, F., Hao, Z., & Ma, L. (2015) · Biomedical Reports · doi:10.3892/br.2015.448 · Cited by 6
Liang, I.-C., Lin, Y.-R., Chien, H., & Liu, K.-R. (2016) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0150 · Cited by 5
Küçük, B., Kadayıfçılar, S., & Eldem, B. M. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.04.18 · Cited by 6
Petrukhin, K. E. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_105 · Cited by 6
Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
He, L., Silva, R. A., Ayoub, N., Moshfeghi, D. M., & Leng, T. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150521-05 · Cited by 6
Vottonen, P. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13706 · Cited by 6
Treder, M., Gaber, A., Rudloff, B., & Eter, N. (2018) · Der Ophthalmologe · doi:10.1007/s00347-018-0746-5 · Cited by 6
“große, prospektiv-randomisierte und doppelverblindete Studien (RCT) über den intravitrealen Einsatz von Bevacizumab, Ranibizumab und Aflibercept bei unterschiedlichen Indikationen publiziert wurden [3, 5, 7, 8, 15, 27, 28], stellt sich zunehmend die Frage des Real-Life-Erfolges dieser Therapie.”
BackgroundUK Aflibercept Users Group, Chatziralli, I., Regan, S. O., Mohamed, R., Talks, J. S., & Sivaprasad, S. (2018) · Eye · doi:10.1038/s41433-018-0114-3 · Cited by 6
“To our knowledge, the specific effect of older age on the efficacy of aflibercept in nAMD has not been addressed in the scientific literature, while older age has been shown to adversely affect the outcomes in patients treated with both bevacizumab and ranibizumab [10, 11] In addition, since it is difficult to study t…”
BackgroundAvastin is as effective as Lucentis in treating wet age related macular degeneration, study finds
Torjesen, I. (2013) · BMJ · doi:10.1136/bmj.f4678 · Cited by 6
Kodjikian, L., Mehanna, C.-J., Cohen, S. Y., Devin, F., Razavi, S., Querques, G., Massin, P., Coscas, F., & Souied, E. H. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211018348 · Cited by 7
Thalgott, V., Feucht, N., Cp, L., & Maier, M. M. (2016) · PubMed · doi:10.1007/s00347-016-0228-6 · Cited by 5
Polypoidal choroidal vasculopathy: In-depth insights and promising future directions
Yang, Z., Zhang, W., Gu, X., Zhao, X., Sadda, S. R., Cheung, C. M. G., Koh, A., Loewenstein, A., Li, B., Wang, C., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101414 · Cited by 5
Ziegler, M., Heimes, B., Book, B., Dietzel, M., Zeimer, M. B., Spital, G., Gutfleisch, M., Pauleikhoff, D., & Lommatzsch, A. P. (2014) · Der Ophthalmologe · doi:10.1007/s00347-014-3137-6 · Cited by 5
Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME
Lombardo, M., Missiroli, F., Cerri, L., Sorge, R. P., Cesareo, M., & Ricci, F. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.17 · Cited by 5
Khan, H., Aziz, A. A., Khanani, Z. A., Khan, H., Mojumder, O., Gahn, G. M., & Khanani, A. M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2387318 · Cited by 5
“This visual acuity outcome was also demonstrated in the Inhibit VEGF in the Age-Related Choroidal Neovascularization Trial (IVAN) [27].”
Rahhal, F. M., Hu, A. Y. H., Humayun, M. S., George, M. S., Javid, C. G., Brown, J., Pitcher, J. D., Dagnon, T., & Kissner, J. (2024) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20240924-01 · Cited by 5
Use of Home Optical Coherence Tomography for Retinal Diseases
Bordbar, D. D., Bhatnagar, A., & Weng, C. Y. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000546 · Cited by 5
OCT-Angiographie bei der exsudativen altersbedingten Makuladegeneration
Lommatzsch, A. P., Farecki, M., Book, B., Heimes, B., & Pauleikhoff, D. (2016) · Der Ophthalmologe · doi:10.1007/s00347-015-0215-3 · Cited by 5
Yao, T., Jin, X., Yuan, Y., Wang, Y., Zhou, Y., He, F., & Wang, Z. (2020) · Journal of Ophthalmology · doi:10.1155/2020/2674780 · Cited by 5
“For patients with AMD, any delay in injection administration during the maintenance phase might not result in a favorable visual outcome and visual function may worsen if treatment is administered discontinuously [3, 15, 16].”
BackgroundPresent and Possible Therapies for Age-Related Macular Degeneration
Kamal, A., Khan, M. A., Agarwal, K., & Loutfi, M. (2014) · Highlights of Ophthalmology · doi:10.5005/hoo-10101-43404 · Cited by 5
Marakis, T. P., Koutsandrea, C., CHATZISTEFANOU, K. I., & Tountas, Y. (2017) · International Ophthalmology · doi:10.1007/s10792-017-0492-8 · Cited by 6
Treatment of macular diseases: an overview of key randomized clinical trials
Валерьевич, Б. Е., Morozova, O. V., & Береснева, Н. С. (2022) · Russian Ophthalmological Journal · doi:10.21516/2072-0076-2021-14-4-137-148 · Cited by 5
“Многоцентровые РКИ CATT (Северная Америка) и IVAN (Великобритания) оценивали эффективность и безопасность применения для лечения неоваскулярной ВМД бевацизумаба (препарат не зарегистрирован для применения в офтальмологии в РФ) и ранибизумаба [6, 7], а также сравнивали режим индивидуального дозирования (PRN) с ежемесяч…”
Age-Related Macular Degeneration
Hellman, J. B., & Yiu, G. C. (2018) · Current practices in ophthalmology · doi:10.1007/978-981-10-8545-1_2 · Cited by 5
Application of Machine Learning to Ranking Predictors of Anti-VEGF Response
Arslan, J., & Benke, K. K. (2022) · Life · doi:10.3390/life12111926 · Cited by 5
Breaking the ocular barrier through nano-lipid carriers to treat intraocular diseases
Giri, S., Badwaik, H. R., & Giri, T. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104867 · Cited by 5
Sawada, T., Wang, X., Sawada, O., Saishin, Y., & Ohji, M. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13002 · Cited by 5
NIHR Ophthalmology Specialty Group, Dawson, S. R., Linton, E., Beicher, K., Gale, R. P., Patel, P. J., Ghanchi, F. D., Beresford, M. W., Poustie, V., Chakravarthy, U., et al. (2018) · Eye · doi:10.1038/s41433-018-0251-8 · Cited by 5
Self-citationKaresvuo, P., Hakkala, L., Kaarniranta, K., Uusitalo, H. M. T., Ojamo, M., & Tuuminen, R. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14376 · Cited by 5
“Bevacizumab and ranibizumab have been demonstrated to be equally effective and safe in wet AMD treatment (CATT Research Group et al. 2011; Chakravarthy et al. 2013; Berg et al. 2016).”
BackgroundCasalino, G., Arrigo, A., Introini, U., Scialdone, A., Coppola, M., Bandello, F. M., Chakravarthy, U., & Parodi, M. B. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1849730 · Cited by 5
Self-citationFreund, K. B., Mrejen, S., & Gallego‐Pinazo, R. (2013) · Current Ophthalmology Reports · doi:10.1007/s40135-013-0034-0 · Cited by 5
Correlation of platelet activating factor and age-related macular degeneration
Nitoda, E., Koutsilieris, M., Brοuzas, D., Koutsandrea, C., Philippou, Α., Ladas, D. S., & Moschos, M. M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.930439 · Cited by 5
Intravitreal administration of bevacizumab: pros and cons
Dashti‐Khavidaki, S., & Abdollahi, M. R. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0110-0 · Cited by 5
Romano, F., Casaluci, M., Valastro, A., Airaldi, M., Milella, P., Giuffrida, F. P., Cozzi, E., Aretti, A., Teo, K. Y. C., Cheung, C. M. G., et al. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14608 · Cited by 4
Blazaki, S. V., Blavakis, E., CHLOUVERAKIS, G. I., Bontzos, G., Chatziralli, I., Smoustopoulos, G., Dimitriou, E., Stavrakakis, A., Kabanarou, S. A., Xirou, T., et al. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06168-0 · Cited by 4
“Prolonged VEGF inhibition is one of the local factors that have been implicated in MA development in nAMD patients under anti-VEGF therapy [7, 30, 31].”
BackgroundType 3 Macular Neovascularization in Age-related Macular Degeneration
Sacconi, R., Forte, P., Corradetti, G., Costanzo, E., Capuano, V., Bousquet, E., Beretta, F., Iannuzzi, S., Polito, M. S., Nicolò, M., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.11.011 · Cited by 4
Mhmud, H., Vermeulen, J., Tigchelaar-Besling, O. A. M., Verbraak, F. D., Barthelmes, D., Gillies, M. C., Ponsioen, T. L., & Klaver, C. C. W. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01178-z · Cited by 4
“The head‑to‑head trials against ranibizumab, IVAN and CATT, only demon‑ strated that bevacizumab was not inferior [20, 21].”
The reactivation time in the treatment of AMD: a forgotten key parameter?
Real, J. P., Luna, J. D., & Palma, S. D. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-3974-0 · Cited by 4
Visual processing in patients with age-related macular degeneration performing a face detection test
Vottonen, P., Kaarniranta, K., Pääkkönen, A., & Tarkka, I. (2017) · Clinical Ophthalmology · doi:10.2147/opth.s132583 · Cited by 4
“Repeated intravitreal anti-VEGF injections are the current treatment for wet AMD and administration of these injections improve patient-reported vision-related function.(24) Consequently, it is also important to understand the possible changes in complex visual processes such as face detection in AMD patients.”
Takahashi, H., Inoue, Y., Tan, X., Inoda, S., Sakamoto, S., Arai, Y., Yanagi, Y., Fujino, Y., & Kawashima, H. (2018) · Clinical ophthalmology · doi:10.2147/opth.s151999 · Cited by 4
“3,4 Large clinical trials such as the CATT (Comparison of AMD Treatments Trials) 2 and IVAN (Inhibition of VEGF in Age-related choroidal Neovascularization) 5 demonstrated that with repeated injections, visual acuity can be maintained over a period of 2 years.”
The role of anti-VEGF therapy in geographic atrophy progression
Plyukhova, A. A., & Budzinskaya, M. V. (2018) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2018134051289 · Cited by 5
Taipale, C., Laine, I., & Tuuminen, R. (2018) · Clinical ophthalmology · doi:10.2147/opth.s188624 · Cited by 5
“A majority of earlier studies have used a fixed-interval treatment protocol with monthly injections,(5,6) or a pro re nata regimen, where injections are given only when signs of active disease are observed.(7,8) Both protocols require monthly visits, which burdens both the patient and the healthcare system.”
BackgroundResultWang, R., Xu, Y., Niu, C., Gao, X., & Xu, X. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.1.16 · Cited by 4
Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD
Chaikitmongkol, V., Bressler, S. B., & Bressler, N. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_111 · Cited by 5
Cheng, S. N., & Leng, T. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160419-09 · Cited by 4
Asahi, M., Wallsh, J. O., Onishi, S., Kuroyama, S., & Gallemore, R. P. (2020) · Clinical ophthalmology · doi:10.2147/opth.s270243 · Cited by 4
Nassisi, M., & Sadda, S. R. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_2 · Cited by 4
PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
Banaee, T., Alwan, S., Kellogg, C., Kornblau, I. S., & El-Annan, J. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i2.9081 · Cited by 4
“The corresponding rates in the IVAN study were 31 and 37% in the discontinuous treatment group.[20, 21] In CATT study, 19 and 13.”
BackgroundMethodResultLong-term outcomes of anti-angiogenic therapy for macular neovascular disorders
Korotkikh, S. A., Валерьевич, Б. Е., Nazarova, N., & Melekhina, E. E. (2016) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2016132176-84 · Cited by 4
Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD
Chaikitmongkol, V., Bressler, S. B., & Bressler, N. M. (2020) · Springer eBooks · doi:10.1007/978-3-319-90495-5_111-1 · Cited by 4
Gismero-Moreno, S., Sánchez, F. J., Soler, N. G., Rivas‐Ruiz, F., & Ruíz, A. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103539 · Cited by 3
Jain, A. S., Motatis, A. K. B., Dharmashekar, C., Shreevatsa, B., Siddesh, V. S., Srinivas, M., Srinivasa, S. M., Ashwini, P., Prasad, M. N. N., Rosell, R., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1645905 · Cited by 3
Riemer, T., Berndt, D., Böker, A., Lehmann, J., Schrifl, U., Rau, S., Rübsam, A., Joussen, A. M., & Zeitz, O. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05952-8 · Cited by 3
Zhou, D., Hu, Y., Qiu, Z., Liu, Z., Jiang, H., Kawasaki, R., & Liu, J. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-03203-w · Cited by 3
“Consequently, early identification and characterization of specific patterns are vital to predict treatment response and consider alternative treatment options [8].”
Backgroundİsmayılov, A. S., Duru, Y., Çağlar, T., Erseven, C., & Ulusoy, M. O. (2024) · International Ophthalmology · doi:10.1007/s10792-024-03198-3 · Cited by 3
Li, Q., Zhou, X., Yang, Y., Zhang, Q., Li, Z., Han, H., Yuan, F., Deng, H., Lei, H., & Duan, Y. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102817 · Cited by 3
Soiberman, U., Levy, R., Schwartz, S., Goldstein, M., Loewenstein, A., & Barak, A. (2013) · European Journal of Ophthalmology · doi:10.5301/ejo.5000408 · Cited by 3
Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration
Sugimoto, M. A., de Toledo, V. D. P. C. P., Cunha, M. R. R., Carregal, V. M., Jorge, R., Leão, P., Fialho, S. L., & Silva‐Cunha, A. (2017) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20170026 · Cited by 3
“05 mL is used in each intravitreal injection for AMD treatment((9-12)).”
BackgroundMethodCapuano, V., Farci, R., Mière, A., Amoroso, F., Bandello, F. M., Souied, E. H., & Querques, G. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170829-04 · Cited by 3
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1191-1433 · Cited by 3
Dual-acting therapeutic proteins for intraocular use
Collins, M., Awwad, S., Ibeanu, N., Khaw, P. T., Guiliano, D. B., Brocchini, S., & Khalili, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.025 · Cited by 3
“Ophthalmology (2012) 119, 1399–1411 [50] Chakravarthy, U.”
Ji, M. H., Callaway, N. F., Ludwig, C. A., Vail, D. G., Al‐Moujahed, A., Rosenblatt, T. R., Leng, T., Sanislo, S. R., & Moshfeghi, D. M. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211001708 · Cited by 3
Bowditch, E., Chu, E. G., Hong, T., & Chang, A. (2021) · Expert Review of Ophthalmology · doi:10.1080/17469899.2021.1933439 · Cited by 3
“Mean BCVA gains were similar between cohorts (p = 0.60): at month 12, 15% and 25% had gained 15 ETDRS letters or more in the monthly and TREX cohorts, respectively.”
MethodInfluentialControversies and Disparities in the Management of Age-Related Macular Degeneration
Fairbanks, A. M., & Husain, D. (2023) · Seminars in Ophthalmology · doi:10.1080/08820538.2022.2152705 · Cited by 3
“bevacizumab compared to ranibizumab with near identical levels of vision over 2 years when given monthly or pro re nata (PRN).(24,25) This level 1 evidence, combined with the significantly lower cost of bevacizumab (and perhaps decreased fear of litigation), led many ophthalmologists to prefer bevacizumab, despite bei…”
BackgroundRowe, L. W., Minturn, R. J., Burgett, L. A., Bracha, P., & Maturi, R. K. (2023) · International Journal of Retina and Vitreous · doi:10.1186/s40942-022-00437-6 · Cited by 3
“In addition, the Inhibition of VEGF in Age-related choroidal Neovascularization (IVAN) trial demonstrated that monthly anti-VEGF treatments are associated with a higher risk and greater development of geographic atrophy (GA) [3].”
BackgroundLamont, T. (2021) · Policy Press eBooks · doi:10.56687/9781447361176 · Cited by 3
Macular Degeneration Drug Prescribing Patterns After Step Therapy Introduction in Medicare Advantage
Liu, A., Anderson, K. E., Levy, J. F., Johnson, T. V., Polsky, D. E., & Anderson, G. F. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.2446 · Cited by 3
Mantel, I., Vitar, R. M. L., & Zanet, S. I. D. (2025) · International Journal of Retina and Vitreous · doi:10.1186/s40942-025-00634-z · Cited by 3
“While the neovascular form of late AMD has been treatable for nearly 2 decades with intravitreal anti-VEGF injections [3–6], the first treatment options for the atrophic form of late AMD have only recently been approved by the Food and Drug Administration (FDA).”
Fliney, G. D., Zukin, L. M., & Hagedorn, C. L. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0013 · Cited by 3
Chia, K. J. W., Gunasekeran, D. V., & Laude, A. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170928-14 · Cited by 3
Treder, M., & Eter, N. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1012-2036 · Cited by 3
“[27] Chakravarthy U, Harding S, Rogers C et al.”
BackgroundPharmacokinetics of Intravitreally Applied VEGF Inhibitors
Krohne, T. U., Holz, F. G., & Meyer, C. H. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_8 · Cited by 3
Lipid Mediators, M2 Macrophages, and Pathological Neovascularization
Swendeman, S. L., & Hla, T. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.003 · Cited by 3
“Current therapeutic approaches for wet AMD focus on VEGF-targeted drugs, which have shown efficacy in multiple studies [3].”
BackgroundHyry, H. I., & Roos, J. C. P. (2018) · Eye · doi:10.1038/s41433-018-0280-3 · Cited by 3
Fellow-Eye Conversion and Treatment in Exudative Age-Related Macular Degeneration
Dow, E. R., Adeghate, J. O., Coombs, P. G., Patel, M. M., D’Amico, D. J., & Kiss, S. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419865990 · Cited by 3
Randazzo, A., Raimondi, R., Fossati, G., Romano, M., Sorrentino, T., Castellani, C., Rossi, C., Cancian, G., & Vinciguerra, P. (2021) · Journal of Ophthalmology · doi:10.1155/2021/7940297 · Cited by 3
“Four major prospective trials were carried out to evaluate the efficacy of this drug: the CATT [4], the IVAN [5], the GEFAL [6], and the LUCAS [7] studies.”
BackgroundKwok, A. K., Lam, W., Fong, A. H. C., Fung, N. S., Ho, M., Iu, L. P. L., Ko, C. K., Mohamed, S., Ng, D. S., Tang, H. H., et al. (2021) · Hong Kong Journal of Ophthalmology · doi:10.12809/hkjo-v25n2-306 · Cited by 3
Foss, A. J. E., Haydock, R., Childs, M., Duley, L., Empeslidis, T., Dhar‐Munshi, S., Montgomery, A. A., Ogollah, R. O., Ozolins, M., Tesha, P. E., et al. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000588 · Cited by 2
Richardson, Q. R., Zhang, Y., Deiner, M. S., Wang, S. T., Bhisitkul, J. M., Arnold, B. F., & Bhisitkul, R. B. (2022) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20220914-01 · Cited by 2
Konukcu, O., Argun, M., Acer, S., Çelik, Ö., Tök, L., Tök, L., & Nazıroğlu, M. (2026) · Biomolecules · doi:10.3390/biom16060883 · Cited by 2
Mehta, N. N., Nagel, I. D., Agnihotri, A. P., Kalaw, F. G. P., Heinke, A., Cheng, L., Bartsch, D., & Freeman, W. R. (2025) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-326124 · Cited by 2
“28 These trials had discussed development and increase in GA compared with preinjection baseline, while our study focused on growth of the atrophy specifically once the disease was in remission.”
Falemban, A. H., Söderberg, K. C., Jonsson, F., Almlöf‐Sarman, S., von Euler, M., & Westborg, I. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17534 · Cited by 2
“(Chakravarthy et al., 2013) and (20.5% vs. 25.7”
InfluentialOta, H., Takeuchi, J., Nonogaki, R., Tamura, K., Kaneko, H., & Nishiguchi, K. M. (2025) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-025-01224-0 · Cited by 2
“Additionally, clinical studies, including randomized controlled trials and systematic reviews, demonstrate a correlation between the frequency of anti-VEGF injections and incidence of RPE atrophy [13, 31, 32].”
IVOM in Österreich 2013 – Eine Auswertung anhand realer Patientenzahlen
Kieselbach, G. F., Vavrovsky, A., & Hochreiter, R. (2016) · Spektrum der Augenheilkunde · doi:10.1007/s00717-016-0294-9 · Cited by 2
Rouic, J. F. L., Breger, D., Peronnet, P., Hermouet-Leclair, E., Alphandari, A., Pousset-Decré, C., Badat, I., & Becquet, F. (2016) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2016.01.007 · Cited by 2
Vanhove, M., Noppen, B., Wagner, J.-M., Bergen, T. V., Barbeaux, P., & Stitt, A. W. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09773-w · Cited by 3
Ertan, E., Çalışkan, N. E., Sabaner, M. C., & Doğan, M. (2021) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_696_20 · Cited by 3
Retinal Angiomatous Proliferation in a Patient with Retinitis Pigmentosa
Király, P., Downes, S. M., & Fischer, M. D. (2023) · Genes · doi:10.3390/genes14071438 · Cited by 2
Self-citationQuiñonez-Alvarado, M. G., Chávez-Hurtado, P., Caro-Palomera, J. C., Niño-Trejo, O. L., Jiménez-Dolores, J. I., Muñoz‐Villegas, P., Baiza-Durán, L. M., & Quintana-Hau, J. D. D. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101711 · Cited by 2
Coney, J., McCoy, J., Sinha, S. B., Sonbolian, N., Zhou, L., Hull, T., Lewis, S. A., MILLER, D. G., Novak, M., Pendergast, S. D., et al. (2023) · Clinical ophthalmology · doi:10.2147/opth.s432957 · Cited by 2
Lee, Y. J., Kang, S., Won, J. Y., Roh, Y., Ra, H., Lee, M. Y., Park, S. P., & Jee, D. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310381 · Cited by 2
Pauleikhoff, L. J. B., Ziegler, M., Bachmeier, I., Yu, S., Armendariz, B. G., & Pauleikhoff, D. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-03946-8 · Cited by 4
Management of diabetic macular edema
Modi, Y. S., Pecen, P. E., & SCHACHAT, A. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-08329-2_8 · Cited by 2
Evidence-based decision making in healthcare in Central Eastern Europe
Ferrario, A., Baltezarevic, D., Novakovic, T., Parker, M., & Samardžić, J. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.946014 · Cited by 2
“Bevacizumab, a drug approved for cancer, was found to be equally effective [9] to ranibizumab for the treatment of wet age-related macular degeneration; however, because it is not approved for this indication, NICE could not recommend its use.”
BackgroundVisusprognose bei der Anti-VEGF-Therapie der AMD
Book, B., Ziegler, M., Heimes, B., Gutfleisch, M., Spital, G., Pauleikhoff, D., & Lommatzsch, A. P. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0308-7 · Cited by 2
Garweg, J. G. (2016) · Der Ophthalmologe · Cited by 2
Impact of the Avastin case on prescribing medicines off‐label
Haughey, S. (2019) · Prescriber · doi:10.1002/psb.1788 · Cited by 2
Rosenblatt, A., Hekselman, I., Rosenblatt, I., Hekselman, I., & Gaton, D. D. (2021) · Israel Journal of Health Policy Research · doi:10.1186/s13584-021-00437-1 · Cited by 2
Pharmacotherapy of Age-Related Macular Degeneration
Laíns, I., Kim, I. K., & Husain, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_112 · Cited by 2
Metadata
- Authors
- Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Chakravarthy, Usha
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 382
- Issue
- 9900
- Pages
- 1258-1267
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2154073405
- Cited by
- 748
- References
- 45
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 36 · 2023: 36 · 2022: 33 · 2021: 84 · 2020: 66 · 2019: 44 · 2018: 74 · 2017: 66 · 2016: 90 · 2015: 77 · 2014: 75 · 2013: 13
- FWCI
- 84.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, cc-by-nc-sa)
- Bristol Research (University of Bristol) (submittedVersion, cc-by-nc-sa)
- ePrints Soton (University of Southampton) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institute for Health and Care Research (07/36/01)
- Health Technology Assessment Programme (07/36/01, /36/01)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, bevacizumab, ranibizumab, anti-VEGF therapy, intravitreal injection, treatment regimen comparison, best-corrected visual acuity, non-inferiority, arterial thrombotic events, long-term outcomes
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Female, Humans, Male, Middle Aged, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
